Having grown into one of the biggest companies in the biotech sphere since...
mRNA vaccines the most promising among emerging COVID-19 vaccines: Poll
Vaccination is being considered as the only way the coronavirus pandemic can be controlled, although a highly effective vaccine is not expected to be available in less than a year.
Pharming begins enrolment in Covid-19 trial of Ruconest
Pharming Group has started enrolment in a clinical trial of Ruconest, a recombinant human C1 inhibitor, for the treatment of hospitalised Covid-19 patients.
Appili expands favipiravir trial to long-term care facilities in US
Appili Therapeutics has secured clearance from the US Food and Drug Administration (FDA) to expand the Phase II Covid-19 clinical trial of favipiravir to long-term care (LTC) facilities in the country.
BMS reports positive data of Opdivo plus Yervoy in MPM
Bristol Myers Squibb (BMS) has reported positive data from the Phase III CheckMate -743
trial of Opdivo (nivolumab) plus Yervoy (ipilimumab) in previously untreated, unresectable malignant pleural mesothelioma (MPM).
Roche’s Tecentriq combination fails in Phase III breast cancer trial
Roche has reported that the combination of Tecentriq (atezolizumab) plus paclitaxel (chemotherapy) failed to meet the primary goal in the Phase III IMpassion131 clinical trial for PD-L1-positive metastatic triple-negative breast cancer (TNBC).
ACTT 3 trial evaluates remdesivir plus interferon beta-1a
The US National Institutes of Health (NIH) has launched the ACTT 3 clinical trial to evaluate Gilead Sciences' remdesivir in combination with interferon beta-1a, an immunomodulator, to treat Covid-19 in hospitalised patients.
Daiichi Sankyo and AstraZeneca partner on lung cancer trial
Daiichi Sankyo and AstraZeneca have partnered to assess patritumab deruxtecan (U3-1402) in combination with Tagrisso (osimertinib) for the treatment of advanced or metastatic non-small cell lung cancer (NSCLC).
Pfizer says Lorbrena met primary goal in lung cancer trial
Pfizer has reported positive results from the Phase III CROWN clinical trial of Lorbrena (lorlatinib) in patients with previously untreated advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC).
Zydus Cadila’s Covid-19 vaccine enters Phase II testing
India-based Zydus Cadila has launched Phase II clinical trials of its Covid-19 vaccine candidate, ZyCoV-D, which showed promise in a Phase I study.
NIH starts trial of antibody treatments for Covid-19 patients
The US National Institutes of Health (NIH) has initiated a Phase III clinical trial, named ACTIV-3, to evaluate various types of monoclonal antibodies as potential treatments for hospitalised Covid-19 patients.